ProCE Banner Events

A Treatment Option for Patients with ER+/HER2-ESR1-mutated mBC Following Progression on Initial ET +/- a CDK4/6i

Join us to gain insights on metastatic breast cancer second line options.

Key Takeaways:

  • Understanding testing and treatment for ESR1-mutated mBC
Time and location

Friday, December 20, 2024

11:00 AM - 11:30 AM Eastern Time (ET)

Virtual

Faculty
Rena Callahan, MD

Associate Clinical Professor
Division of Hematology Oncology
UCLA David Geffen School of Medicine 

Sponsored By

Stemline

ProCE Banner